Ensuring public trust in digital therapeutics: a pharmacopeial perspective.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33769853.
- Also identified by DOI 10.18553/jmcp.2021.27.4.533 and PMC identifier 10390969.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
<b>DISCLOSURES:</b> No funding supported the writing of this commentary. The author is employed by US Pharmacopeia. This article was requested by JMCP as a response to the companion Viewpoints article "Decision Makers Need an Approach to Determine Digital Therapeutic Product Quality, Access, and Appropriate Use" by Parcher and Coder (see page 536). Digital Therapeutics Alliance, which is mentioned in this article, is a member of the USP Convention.
Medical subject headings
- Pharmacopoeias as Topic
- Telemedicine
- Trust